High Court of Delhi at New Delhi | Decided: 22 September 2015 CS (OS) No. 3812 of 2014 & I.A. No. 24580 of 2014 Bench: Hon’ble Mr. Justice Manmohan Singh Citation: 2015 SCC OnLine Del 13243 | (2015) 65 PTC 285 (Del)
Background
Novartis AG, a Swiss multinational pharmaceutical corporation, and its affiliate were the registered proprietors of Indian Patent No. 240530, granted in respect of a pharmaceutical compound used in the treatment of chronic obstructive pulmonary disease, commonly known as COPD. The patented compound was indacaterol maleate, a long-acting beta-2 adrenoceptor agonist used as a bronchodilator, marketed by Novartis under the brand name Onbrez Breezhaler in India. Indacaterol maleate is administered through inhalation once daily and was regarded at the time of the litigation as a clinically significant advance in the management of COPD, a progressive and debilitating respiratory disease that affects hundreds of millions of patients worldwide and represents a major cause of morbidity and mortality in India. The patent covered the maleate salt form of indacaterol, which is the specific salt used in the commercial product, and claimed priority from an earlier application filed in the United Kingdom.
Cipla Limited, India’s prominent generic pharmaceutical manufacturer with a well-established presence in the respiratory medicine segment, announced its intention to launch a generic version of indacaterol under its own brand, at a price significantly lower than that charged by Novartis for Onbrez Breezhaler. Cipla’s product was based on indacaterol in a different salt form the acetate salt rather than the maleate salt covered by the Novartis patent. Cipla maintained that its product used a different salt form that was not covered by the claims of Patent No. 240530, and that it was therefore entitled to market its product without infringing Novartis’s patent. The launch of a generic indacaterol product by Cipla at a substantially lower price would have significant implications for patient access to this class of COPD medication in India, given the large patient population affected by the disease and the relatively high cost of the branded product.
Novartis filed the present suit for patent infringement and simultaneously applied for an ad-interim injunction under Order XXXIX Rules 1 and 2 of the Civil Procedure Code, 1908, seeking to restrain Cipla from manufacturing, selling, distributing or in any manner dealing in any product containing indacaterol that infringed its Patent No. 240530. Novartis contended that despite Cipla’s claim to be using the acetate salt, the product as actually manufactured and sold by Cipla contained, or inevitably converted to, the maleate salt covered by the patent, and that Cipla’s product therefore infringed the patent whether or not it was described as using the acetate salt. Novartis also contended that Cipla’s infringement was deliberate and that an injunction was necessary to protect the commercial value of its patent, particularly given the proximity of Cipla’s product launch to the filing of the suit.
Cipla resisted the injunction application on multiple grounds. It contended that its product genuinely used the acetate salt of indacaterol and did not infringe the Novartis patent which was confined to the maleate salt. It further challenged the validity of Patent No. 240530 on the grounds that the maleate salt of indacaterol did not satisfy the requirements of Section 3(d) of the Patents Act, 1970, as it did not demonstrate significantly enhanced efficacy over indacaterol in its known forms. Cipla also raised the public interest argument that the grant of an injunction would restrict patient access to an affordable version of an important COPD medication, and argued that the balance of convenience and the irreparable harm analysis should take into account the interests of the large population of COPD patients who stood to benefit from access to a cheaper generic product. The case thus raised issues at the intersection of patent claim construction, Section 3(d) validity, and the by-then well-established public interest dimension of pharmaceutical patent injunctions in India.
The proceedings were significant not only for their commercial importance to both Novartis and Cipla but also because they arose in the immediate aftermath of the Supreme Court’s landmark 2013 decision in Novartis AG v. Union of India, which had definitively interpreted Section 3(d) of the Patents Act and had significantly raised the bar for the patentability of pharmaceutical derivatives and salt forms. The shadow of that decision loomed large over the present proceedings, particularly in relation to Cipla’s challenge to the validity of the maleate salt patent under Section 3(d), and the court was required to consider whether the principles laid down by the Supreme Court in the Novartis-Glivec case were applicable to the facts of the present dispute.
Issues for Determination
- Whether Novartis established a prima facie case that Cipla’s indacaterol product infringed Indian Patent No. 240530, having regard to the claim that Cipla’s product used the acetate salt of indacaterol rather than the maleate salt covered by the patent.
- Whether the technical question of which salt form of indacaterol was present in Cipla’s product maleate or acetate and whether one salt form could convert to or be equivalent to the other in pharmaceutical and clinical terms, raised triable issues of fact and expert evidence that precluded the grant of an interim injunction.
- Whether Cipla raised a credible and prima facie tenable challenge to the validity of Patent No. 240530 under Section 3(d) of the Patents Act, 1970, specifically whether the maleate salt of indacaterol demonstrated significantly enhanced therapeutic efficacy over indacaterol in previously known forms so as to clear the statutory bar imposed by that provision.
- What is the correct approach to claim construction in determining whether a product using a different salt form of a patented compound infringes the patent, and specifically whether the doctrine of equivalents has application in Indian patent law at the interlocutory stage.
- Whether the public interest in access to affordable COPD medication for the large population of Indian patients suffering from this disease constitutes a relevant and weighty factor in the balance of convenience analysis, and how it should be weighed against the patentee’s commercial interest in protecting its patent monopoly.
- Whether the balance of convenience and irreparable harm analysis favoured the grant or refusal of an interim injunction, having regard to the financial resources of both parties, the stage of Cipla’s product launch, and the broader public interest considerations.
Key Holdings of the Court
First, the court held that Novartis had established a prima facie case of infringement at the threshold level, finding that the Novartis patent covered the maleate salt of indacaterol and that Cipla’s product, while described as using the acetate salt, raised genuine questions about whether the active ingredient in the final product was or could become equivalent to the patented compound. However, the court found that this prima facie case was far from clear or unambiguous given the technical complexity of the salt form dispute.
Second, the court held that the question of which salt form of indacaterol was present in Cipla’s product, and whether the acetate salt was therapeutically or pharmaceutically equivalent to the maleate salt covered by the patent, was a deeply technical question of fact that could not be resolved on the basis of the affidavit evidence available at the interlocutory stage. This uncertainty in the infringement analysis significantly weakened the case for granting an interim injunction.
Third, the court held that Cipla had raised a credible and prima facie substantiated challenge to the validity of Patent No. 240530 under Section 3(d) of the Patents Act, 1970. The court found that the question of whether the maleate salt of indacaterol demonstrated significantly enhanced therapeutic efficacy over previously known forms of indacaterol was a genuine triable issue in the light of the Supreme Court’s authoritative interpretation of Section 3(d) in the Novartis-Glivec case. The court held that this validity challenge could not be dismissed summarily at the interlocutory stage.
Fourth, the court reaffirmed and applied the principle established by the Division Bench in Cipla v. Roche that public interest in access to affordable medicines for serious diseases is a legitimate and weighty consideration in the balance of convenience analysis in pharmaceutical patent infringement cases. The court found that the large and underserved population of COPD patients in India who would benefit from access to an affordable generic indacaterol product was a factor that carried real weight in the balance of convenience.
Fifth, the court held that damages would constitute an adequate remedy for Novartis in the event that an injunction was refused and Cipla was ultimately found to have infringed, given Cipla’s substantial financial resources, its open and transparent marketing of the product, and the absence of any circumstances suggesting that a damages award could not be enforced. The court found that Novartis had not demonstrated that the refusal of an injunction would cause it harm that could not be adequately compensated in money.
Sixth, the court refused the ad-interim injunction sought by Novartis. The application was dismissed, and the suit was directed to proceed to trial expeditiously, with directions for the early filing of evidence and the appointment of a scientific adviser to assist the court in understanding the technical aspects of the dispute.
Statutory Provisions Involved
Section 48 of the Patents Act, 1970 confers upon the patentee the exclusive right to prevent third parties from making, using, offering for sale, selling or importing the patented product in India without consent. This provision established the legal basis of Novartis’s claim to injunctive relief and defined the scope of the exclusive rights whose alleged violation formed the foundation of the infringement suit.
Section 3(d) of the Patents Act, 1970 as amended by the Patents (Amendment) Act, 2005 provides that the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance shall not constitute a patentable invention. The Explanation to this provision specifically identifies salts as among the new forms of a known substance that are presumed to be the same substance unless they differ significantly in efficacy. Cipla’s primary validity challenge was mounted under this provision, and the court was required to assess whether the challenge raised a prima facie triable question in the light of the Supreme Court’s interpretation of Section 3(d) in the Novartis-Glivec judgment.
Section 64(1) of the Patents Act, 1970 enumerates the grounds on which a patent may be revoked, including want of novelty, absence of inventive step, and non-compliance with the requirements of patentable subject matter under Section 3. Cipla’s invalidity challenge at the interlocutory stage was framed with reference to Section 64, and the court assessed whether the challenge raised genuine triable issues under the relevant grounds of revocation.
Section 107 of the Patents Act, 1970 provides that every ground on which a patent may be revoked under Section 64 is available as a defence in infringement proceedings. This provision enabled Cipla to raise the invalidity of Patent No. 240530 as a defence in the infringement suit without being required to initiate separate revocation proceedings before the IPAB, and the court considered the invalidity defence within the framework of the interlocutory injunction analysis.
Section 48A of the Patents Act, 1970 relating to compulsory licences, though not directly invoked in the proceedings, formed part of the broader statutory context within which the court considered the public interest dimension of the case, as the provision reflects the legislative policy of ensuring that patented products are available to the public at reasonably affordable prices.
Order XXXIX Rules 1 and 2 of the Civil Procedure Code, 1908 govern the grant of temporary injunctions and require the applicant to establish a prima facie case, demonstrate that the balance of convenience lies in its favour, and show that refusal of the injunction would cause irreparable harm. The court applied this framework as the analytical structure for its assessment of the injunction application, though it supplemented the framework with the public interest considerations articulated in the Cipla v. Roche precedent.
Reasoning of the Court
The court approached the injunction application against the backdrop of the rapidly developing body of Indian jurisprudence on pharmaceutical patent injunctions that had taken shape in the years following the Cipla v. Roche Division Bench decision. The court recognized that pharmaceutical patent cases involving generic challenges to branded medicines occupied a special place in the jurisprudence of patent injunctions, because they inevitably implicated not only the commercial interests of the parties but also the broader public interest in access to essential medicines. The court therefore applied the tripartite test of prima facie case, balance of convenience and irreparable harm with a degree of contextual sensitivity that was informed by both the Cipla v. Roche precedent and the Supreme Court’s Novartis-Glivec judgment.
On the prima facie case of infringement, the court conducted a careful examination of the patent claims and the technical evidence relating to Cipla’s product. The central difficulty was the salt form dispute. Novartis’s patent covered the maleate salt of indacaterol specifically, while Cipla maintained that its product used the acetate salt. Novartis argued that the acetate salt converted to or was equivalent to the maleate salt in the body and that the distinction was therefore without clinical or legal significance. Cipla disputed this and maintained that the acetate and maleate salts were chemically and pharmacologically distinct. The court found that this technical dispute could not be resolved on the basis of the competing affidavits of the parties’ experts at the interlocutory stage, as it required a detailed examination of the chemistry of the two salt forms, their respective bioavailability profiles, and their in vivo behaviour. The court noted that in pharmaceutical chemistry, different salt forms of the same active pharmaceutical ingredient are routinely treated as distinct compounds with potentially different properties, and that Cipla’s claim to be using a different salt form was not inherently implausible.
On the validity challenge under Section 3(d), the court’s reasoning was heavily shaped by the Supreme Court’s 2013 decision in Novartis AG v. Union of India. That decision had established that the efficacy referred to in Section 3(d) is therapeutic efficacy, and that an applicant seeking to patent a new salt form of a known pharmaceutical compound must demonstrate enhanced therapeutic efficacy of the salt form over the known compound — not merely enhanced physical or chemical properties. The court found that Cipla had raised a credible question of whether the maleate salt of indacaterol demonstrated significantly enhanced therapeutic efficacy over indacaterol in previously known forms. The court noted that indacaterol itself was a known compound before the priority date of the Novartis patent, and that the selection and development of the maleate salt required Novartis to demonstrate that the salt form provided a genuine therapeutic advantage. Whether the available evidence established this to the standard required by Section 3(d) as interpreted by the Supreme Court was a question that required full examination at trial.
On the balance of convenience and public interest, the court applied the framework established by the Cipla v. Roche Division Bench, holding that the large population of COPD patients in India who would benefit from access to a more affordable generic product was a legitimate and weighty consideration. The court observed that COPD is a chronic, progressive and ultimately fatal disease that requires long-term medication, and that the cost of branded inhalation therapy places a continuous and substantial financial burden on patients and their families. Making an affordable generic available would benefit not only those who could not afford the branded product but also the broader healthcare system. The court balanced this against Novartis’s commercial interest in enforcing its patent monopoly and found that the balance tipped in favour of refusing the injunction, particularly given the availability of a damages remedy and the absence of evidence that Novartis would suffer irreparable harm from the refusal.
The court also addressed the question of irreparable harm with careful attention to the specific circumstances of both parties. It found that Novartis, as a large multinational pharmaceutical company with substantial financial resources, was not in a position where the commercial impact of Cipla’s competition, if Cipla ultimately lost the suit, could not be quantified and compensated in damages. Cipla’s marketing of its product was open and transparent, and its books of account would be available to establish the quantum of any damages award. The court contrasted this with the position of the COPD patients who would lose access to an affordable medication if the injunction were granted a harm that was both unquantifiable in monetary terms and potentially irreversible in medical terms.
Doctrinal Significance
The Novartis v. Cipla judgment of 2015 represents an important milestone in the consolidation of the public interest framework for pharmaceutical patent injunctions in India that had been initiated by the Cipla v. Roche Division Bench decision of 2012. By applying and reinforcing the principle that public interest in access to affordable medicines is a substantive and weighty consideration in the balance of convenience analysis rather than a sentimental or policy consideration that lies outside the strict legal framework the court contributed to the solidification of this principle as an established feature of Indian pharmaceutical patent injunction jurisprudence.
The judgment’s treatment of the salt form dispute and the doctrine of equivalents is also doctrinally significant. By refusing to resolve the question of whether the acetate and maleate salt forms of indacaterol were equivalent for the purposes of infringement at the interlocutory stage, and by insisting that such a technically complex question required full trial with expert evidence, the court reinforced the principle that pharmaceutical patent claim construction is a matter of considerable technical complexity that courts must approach with appropriate epistemic humility at the interim stage. This approach is consistent with the emerging recognition in Indian patent jurisprudence that the grant or refusal of interim injunctions in pharmaceutical patent cases should be grounded in an informed technical assessment rather than a formulaic application of the standard test.
The judgment also represents an important application of the Supreme Court’s Section 3(d) jurisprudence from the Novartis-Glivec case to a new category of pharmaceutical salt patents. By treating the Section 3(d) challenge to a salt form patent as a credible and prima facie tenable validity challenge that warranted serious consideration at the interlocutory stage, the court demonstrated that the Novartis-Glivec decision had created a genuinely demanding standard for the patentability of pharmaceutical salt forms that would be applied rigorously by courts in infringement proceedings. This has implications for the broader landscape of pharmaceutical patent litigation in India, signalling to innovator companies that salt form patents will face serious scrutiny under Section 3(d) and that courts will not readily grant injunctions to enforce such patents in the face of credible invalidity challenges.
The decision also contributes to the developing Indian jurisprudence on the adequacy of damages as a remedy in patent cases. By carefully examining whether the specific circumstances of Novartis rendered a damages remedy inadequate and finding that they did not the court provided useful guidance on the factors relevant to this inquiry, including the financial resources of the parties, the transparency of the alleged infringer’s commercial operations, and the quantifiability of the patentee’s loss. This analysis is a valuable complement to the more mechanical treatment of the irreparable harm requirement that characterizes some earlier decisions.
Finally, the judgment’s direction for the appointment of a scientific adviser to assist the court in understanding the technical aspects of the indacaterol salt form dispute reflects a growing judicial recognition in India that complex pharmaceutical patent litigation requires the court to be equipped with appropriate technical assistance. The use of scientific advisers or court-appointed experts in patent cases is an important procedural development that enables Indian courts to engage more confidently and accurately with the technical substance of patent disputes, reducing the risk that outcomes at the interlocutory stage are distorted by the asymmetric technical expertise of the parties’ legal teams.
Articles Case Laws Copyright Article Copyright case laws Patent Article patent case laws Trademark Article Trademark case laws